X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13591) 13591
Publication (836) 836
Book Review (133) 133
Magazine Article (48) 48
Book Chapter (23) 23
Conference Proceeding (19) 19
Book / eBook (16) 16
Paper (2) 2
Journal / eJournal (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9715) 9715
hypolipidemic agents - therapeutic use (7606) 7606
male (7009) 7009
animals (4639) 4639
female (4513) 4513
hypolipidemic agents - pharmacology (3998) 3998
index medicus (3937) 3937
middle aged (3616) 3616
rats (2619) 2619
aged (2542) 2542
hyperlipidemias - drug therapy (2444) 2444
adult (2436) 2436
pharmacology & pharmacy (2222) 2222
risk factors (2203) 2203
cholesterol (2047) 2047
triglycerides - blood (1983) 1983
hypolipidemic agents - administration & dosage (1713) 1713
lipids - blood (1711) 1711
cholesterol - blood (1668) 1668
cardiac & cardiovascular systems (1431) 1431
treatment outcome (1392) 1392
hypolipidemic agents - adverse effects (1340) 1340
cholesterol, ldl - blood (1334) 1334
mice (1274) 1274
atherosclerosis (1269) 1269
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1188) 1188
lipids (1159) 1159
medicine, general & internal (1140) 1140
cholesterol, hdl - blood (1119) 1119
liver - drug effects (1057) 1057
dyslipidemias - drug therapy (1032) 1032
coronary-heart-disease (1021) 1021
cardiovascular diseases - prevention & control (985) 985
drug therapy, combination (980) 980
statins (968) 968
liver - metabolism (952) 952
risk (889) 889
hypercholesterolemia - drug therapy (871) 871
hyperlipidemias - blood (859) 859
peripheral vascular disease (826) 826
prevention (807) 807
endocrinology & metabolism (793) 793
diabetes (783) 783
time factors (779) 779
biochemistry & molecular biology (775) 775
rats, wistar (743) 743
triglycerides (732) 732
hyperlipidemia (719) 719
clinical trials as topic (709) 709
dose-response relationship, drug (709) 709
fenofibrate - therapeutic use (706) 706
metabolism (692) 692
antihypertensive agents - therapeutic use (684) 684
cardiovascular disease (679) 679
simvastatin (679) 679
fenofibrate (666) 666
hypoglycemic agents - therapeutic use (666) 666
hypercholesterolemia (665) 665
chemistry, medicinal (640) 640
rats, sprague-dawley (635) 635
disease (631) 631
cardiovascular-disease (626) 626
research (623) 623
diabetes mellitus, type 2 - drug therapy (619) 619
hypolipidemic agents - chemistry (604) 604
care and treatment (600) 600
dyslipidemia (595) 595
hyperlipidemias - complications (595) 595
coronary disease - prevention & control (590) 590
myocardial-infarction (590) 590
therapy (575) 575
double-blind method (571) 571
analysis (566) 566
drug therapy (556) 556
health aspects (550) 550
diet (543) 543
mortality (542) 542
lipoproteins (536) 536
fenofibrate - pharmacology (534) 534
biomarkers - blood (527) 527
liver (526) 526
niacin - therapeutic use (518) 518
low density lipoproteins (514) 514
lipid metabolism (508) 508
cardiovascular diseases - etiology (507) 507
diabetes mellitus, type 2 - complications (507) 507
plant extracts - pharmacology (506) 506
lipoproteins - blood (500) 500
gemfibrozil (493) 493
hypoglycemic agents - pharmacology (492) 492
insulin resistance (490) 490
hypertension - drug therapy (487) 487
blood glucose - metabolism (478) 478
hypolipidemic agents (477) 477
anticholesteremic agents (465) 465
secondary prevention (465) 465
aged, 80 and over (464) 464
oxidative stress (463) 463
cardiovascular diseases (462) 462
practice guidelines as topic (453) 453
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11985) 11985
German (317) 317
French (254) 254
Russian (247) 247
Chinese (183) 183
Spanish (144) 144
Japanese (119) 119
Polish (85) 85
Italian (79) 79
Czech (66) 66
Hungarian (38) 38
Portuguese (26) 26
Danish (19) 19
Norwegian (18) 18
Swedish (18) 18
Dutch (15) 15
Finnish (12) 12
Ukrainian (10) 10
Romanian (8) 8
Slovak (7) 7
Lithuanian (6) 6
Bulgarian (5) 5
Croatian (4) 4
Korean (4) 4
Hebrew (2) 2
Serbian (2) 2
Bosnian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Nature Reviews Drug Discovery, ISSN 1474-1776, 2014, Volume 13, Issue 6, pp. 433 - 444
The liver X receptors (LXRs) are pivotal regulators of lipid homeostasis in mammals. These transcription factors control the expression of a battery of genes... 
BINDING CASSETTE TRANSPORTER | BILIARY STEROL SECRETION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | REVERSE CHOLESTEROL TRANSPORT | ALZHEIMERS-DISEASE | LOW-DENSITY-LIPOPROTEIN | PROLIFERATOR-ACTIVATED RECEPTOR | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | EXPRESSION IN-VITRO | ATHEROSCLEROSIS SUSCEPTIBILITY | LXR-ALPHA | Intestines - drug effects | Drugs, Investigational - pharmacology | Humans | Drugs, Investigational - therapeutic use | Intestines - metabolism | Orphan Nuclear Receptors - metabolism | Brain - metabolism | Drugs, Investigational - chemistry | Protein Isoforms - metabolism | Liver - drug effects | Alzheimer Disease - prevention & control | Liver X Receptors | Drug Design | Neurons - metabolism | Hypolipidemic Agents - chemistry | Drug Evaluation, Preclinical | Neurons - drug effects | Hypolipidemic Agents - adverse effects | Nerve Tissue Proteins - antagonists & inhibitors | Molecular Targeted Therapy - adverse effects | Atherosclerosis - drug therapy | Liver - metabolism | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Clinical Trials as Topic | Hypolipidemic Agents - pharmacology | Nootropic Agents - adverse effects | Nootropic Agents - chemistry | Drug Discovery | Atherosclerosis - metabolism | Brain - drug effects | Nerve Tissue Proteins - metabolism | Orphan Nuclear Receptors - antagonists & inhibitors | Animals | Signal Transduction - drug effects | Alzheimer Disease - metabolism | Lipid Metabolism - drug effects | Hypolipidemic Agents - therapeutic use | Atherosclerosis - prevention & control | Nootropic Agents - pharmacology | Protein Isoforms - antagonists & inhibitors | Care and treatment | Research | Drug discovery | Patient outcomes | Risk factors | Atherosclerosis
Journal Article
2005, 1. Aufl., Handbook of experimental pharmacology, ISBN 3540225692, Volume 170, xii, 816
This book gives an overview on important mechanisms involved in atherosclerosis and thereby presents targets some of which are used and others which may be... 
Atherosclerosis | Toxicology | Angiology | Biomedicine | Pharmacology/Toxicology | Cardiology | Metabolic Diseases
Book
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 5/2008, Volume 25, Issue 5, pp. 1063 - 1074
To assess the consequences of multiple inhibitors and differential inhibition mechanisms on the prediction of 12 gemfibrozil drug–drug interactions (DDIs). In... 
Biomedical Engineering | Biochemistry, general | CYP2C8 | Biomedicine | enzyme inhibition | Pharmacy | drug–drug interactions | Medical Law | Pharmacology/Toxicology | gemfibrozil | OATP1B1 | Enzyme inhibition | Drug-drug interactions | Gemfibrozil | PARALLEL PATHWAYS | CYP3A4 IN-VITRO | HUMAN LIVER-MICROSOMES | TRANSPLANT RECIPIENTS | HEPATIC-UPTAKE | CHEMISTRY, MULTIDISCIPLINARY | ATORVASTATIN | drug-drug interactions | PHARMACOKINETICS | PLASMA-CONCENTRATIONS | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | CYCLOSPORINE | Cell Line | Cytochrome P-450 CYP2C8 | Hypolipidemic Agents - adverse effects | Predictive Value of Tests | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Area Under Curve | Humans | Immunosuppressive Agents - pharmacokinetics | Enzyme Inhibitors - pharmacology | Gemfibrozil - pharmacokinetics | Gemfibrozil - adverse effects | Aryl Hydrocarbon Hydroxylases - metabolism | Carrier Proteins - metabolism | Drug Interactions | Glucuronides - metabolism | Cyclosporine - adverse effects | Cyclosporine - pharmacokinetics | Immunosuppressive Agents - adverse effects | Kinetics | Hypolipidemic Agents - pharmacokinetics | Databases, Factual | Physiological aspects | Complications and side effects | Analysis | Drug interactions | Low density lipoproteins | Enzymes | Biomedical research | Inhibitor drugs | Predictions | Pharmacology | Models | Metabolism
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 5, pp. 1078 - 1089
Background & Aims We performed a genome-wide association study (GWAS) to identify genetic risk factors for drug-induced liver injury (DILI) from licensed drugs... 
Gastroenterology and Hepatology | Side Effect | Medication | Liver Damage | Anti-Fungal Agent | POPULATION | SUSCEPTIBILITY | RISK | TERBINAFINE | TICLOPIDINE | HEPATITIS | CLASS-I | HEPATOTOXICITY | GASTROENTEROLOGY & HEPATOLOGY | T-CELLS | ANTIGEN | Antifungal Agents - adverse effects | Naphthalenes - adverse effects | Humans | Middle Aged | Male | Sertraline - adverse effects | Fenofibrate - adverse effects | Chromosomes, Human, Pair 2 - genetics | Ticlopidine - adverse effects | Female | Odds Ratio | Chemical and Drug Induced Liver Injury - etiology | Platelet Aggregation Inhibitors - adverse effects | Hypolipidemic Agents - adverse effects | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Genes, MHC Class I - genetics | Chemical and Drug Induced Liver Injury - genetics | Terbinafine | Phenotype | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Alleles | HLA-A Antigens - genetics | Polymorphism, Single Nucleotide | Antidepressive Agents - adverse effects | Drugs | Medical research | Liver diseases | Liver | Genes | Genomics | Risk factors | Genetic polymorphisms | Analysis | Gastrointestinal diseases | Medicine, Experimental | Genetic research | Trade and professional associations | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Hépatology and Gastroenterology | side effect | medication | anti-fungal agent | liver damage | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Gastroenterologi | Klinisk medicin
Journal Article
American Journal of Cardiovascular Drugs, ISSN 1175-3277, 04/2010, Volume 10, Issue 2, pp. 95 - 103
Background The Polycap™ (polypill; aspirin [acetylsalicylic acid], ramipril, simvastatin, atenolol, and hydrochlorothiazide) was found to be safe and effective... 
Drug-interactions | Ramipril, pharmacokinetics | Aspirin, pharmacokinetics | Hydrochlorothiazide, pharmacokinetics | Hydrochlorothiazide/atenolol/ramipril/simvastatin/aspirin, pharmacokinetics | Salicylic-acid, pharmacokinetics | Atenolol, pharmacokinetics | Risk-factors | Hydrochlorothiazide/atenolol/ramipril/simvastatin/aspirin, drug interactions | Simvastatin, pharmacokinetics | Cardiovascular-disorders, treatment | Pharmacotherapy | Medicine & Public Health | Cardiology | Pharmacology/Toxicology | CYTOCHROME-P450 | CARDIAC & CARDIOVASCULAR SYSTEMS | LOW-DOSE ASPIRIN | PHARMACOKINETICS | METABOLISM | FORMULATIONS | SIMVASTATIN ACID | CARDIOVASCULAR-DISEASE | PHARMACOLOGY & PHARMACY | BIOEQUIVALENCE | Hydrochlorothiazide - pharmacokinetics | Simvastatin - adverse effects | Area Under Curve | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Aspirin - pharmacokinetics | Biological Availability | Male | Aspirin - administration & dosage | Ramipril - administration & dosage | Young Adult | Capsules | Drug Interactions | Aspirin - adverse effects | Atenolol - pharmacokinetics | Platelet Aggregation Inhibitors - administration & dosage | Adult | Platelet Aggregation Inhibitors - pharmacokinetics | Atenolol - administration & dosage | Ramipril - adverse effects | Tandem Mass Spectrometry - methods | Platelet Aggregation Inhibitors - adverse effects | Hydrochlorothiazide - adverse effects | Cardiovascular Diseases - etiology | Hypolipidemic Agents - adverse effects | Administration, Oral | Simvastatin - administration & dosage | Risk Factors | Ramipril - pharmacokinetics | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - pharmacokinetics | Simvastatin - pharmacokinetics | Antihypertensive Agents - adverse effects | Cross-Over Studies | Adolescent | Hypolipidemic Agents - administration & dosage | Atenolol - adverse effects | Chromatography, Liquid - methods | Hypolipidemic Agents - pharmacokinetics | Drug Combinations | Prevention | Complications and side effects | Drug interactions | Dosage and administration | Research | Cardiovascular diseases | Risk factors | Cardiovascular agents
Journal Article
Journal Article